As we approach the end of 2024, join us as we look back at some highlights of Barts Cancer Institute’s news stories this year. Thank you to our amazing staff, students and partners for making this progress possible.
January
In January, the Centre for Epigenetics launched, a £3m collaboration between researchers at Queen Mary University of London and Barts Health NHS Trust, funded by Barts Charity. The team, co-led by BCI's Dr Gabriella Ficz will investigate how the marks on DNA in blood can be used to detect disease at an early stage.
February
Professor Peter Szlosarek and team published groundbreaking results of the ATOMIC-meso clinical trial in February, which showed that an innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options.
March / April
The BCI’s inaugural Director Professor Nick Lemoine steps down after leading the institute for 20 years. We celebrated Professor Lemoine’s role in shaping the institute and welcomed the BCI’s new Director, Professor Nitzan Rosenfeld.
April
Dr Oliver Pearce, Dr Priyanka Hirani and their team revealed how a protein affects immune cells' ability to fight triple-negative breast cancer. The findings could help more patients benefit from immunotherapies.
May
Professor Fran Balkwill was elected as a Fellow of The Royal Society for her invaluable contributions to cancer research and public engagement.
May
Professor Tom Powles is recognised by TIME Magazine in their inaugural TIME100 Health, a new annual list of 100 individuals who most influenced global health this year.
July
Professor John Gribben won the European Hematology Association’s prestigious José Carreras Award in recognition of his exceptional achievements in shaping the landscape of haematological research.
July
The BCI’s STARS work experience programme was expanded to other sites within the CRUK City of London Centre. STARS aims to engage and inspire young people from schools with historically low university attendance by giving them the opportunity to try out their lab skills side-by-side with our researchers.
September
Professor Tom Powles and Professor Peter Schmid announced practice-changing results of two phase III clinical trials, showing that innovative chemotherapy-immunotherapy drug combinations improve survival for bladder cancer and triple-negative breast cancer, two hard-to-treat cancers.
October
Dr Paolo Gallipoli, Dr Vilma Dembitz and team uncover a potential new approach to treating acute myeloid leukaemia (AML) by targeting the way cancer cells metabolise fat.
October
Professor Yaohe Wang, Dr Jun (Alex) Wang and team published new results revealing that oesophageal squamous cell carcinoma (ESCC), is composed of four distinct subtypes, paving the way to more personalised treatments.
November
Professor Yaohe Wang and his team published results from a phase I clinical trial, showing that their oncolytic virus treatment was safe and effective in people with glioblastoma, supporting progression to phase II clinical trials.
Category: General News
No comments yet